Related Experiment Video

Updated: Nov 22, 2025

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma
08:18

Analysis of Lymph Node Volume by Ultra-High-Frequency Ultrasound Imaging in the Braf/Pten Genetically Engineered Mouse Model of Melanoma

Published on: September 8, 2021

3.2K

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma

Paola Savoia1, Elisa Zavattaro2, Ottavio Cremona3

  • 1Department of Health Science, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy.

International Journal of Molecular Sciences
|January 9, 2021
PubMed

Insights

Mitogen-activated protein kinase (MAPK) pathway mutations drive melanoma. Combination therapies targeting BRAF inhibitors show promise in overcoming resistance and improving treatment outcomes for advanced melanoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Dermatology

Background:

  • Melanoma treatment has been revolutionized by targeting mitogen-activated protein kinase (MAPK) pathway mutations.
  • BRAF inhibitors have significantly improved outcomes but face challenges due to resistance mechanisms.

Purpose of the Study:

  • To review the clinical efficacy of BRAF inhibitors in advanced melanoma.
  • To explore strategies for overcoming resistance to BRAF inhibitors.

Main Methods:

  • Review of clinical trial data and scientific literature on BRAF inhibitor therapy in melanoma.
  • Analysis of intrinsic and extrinsic resistance mechanisms.
  • Evaluation of combination therapy approaches.

Main Results:

  • Combination therapies demonstrate success in overcoming BRAF inhibitor resistance.
  • Reduced side effects observed with combination therapy due to less paradoxical MAPK pathway activation.
  • Emerging strategies include targeted inhibitors, intermittent dosing, and combination with immune checkpoint inhibitors.

Conclusions:

  • BRAF inhibitors are crucial in advanced melanoma management.
  • Combination therapies and novel strategies are essential to enhance treatment durability and efficacy.
  • Further research is needed to optimize dosing, tolerability, and administration sequences.
Keywords:
BRAF inhibitorsmetastatic melanomaresistancetarget therapy

More Related Videos

A Melanoma Patient-Derived Xenograft Model07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.8K
Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.2K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.1K
The Retinoblastoma Gene01:20

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K